Henry Meds is one of several telehealth platforms selling flat monthly access to GLP-1 treatment, and it competes mostly on price and simplicity rather than on anything unique to its medicine. The real differences between it and rivals like Ro, Hims and Hers, Henry’s own tier options, and LillyDirect come down to three things: whether the drug is brand or compounded, how much clinician contact is included, and what the price actually is after the first month. On the medication itself, most of them overlap.
What is Henry Meds actually selling?
Henry Meds built its name on low, predictable cash pricing for compounded semaglutide and tirzepatide. That is worth stating plainly, because it shapes everything else. Compounded medication is prepared by a compounding pharmacy and is not an FDA-approved product. It has not gone through the approval process that generated the trial evidence for Wegovy or Zepbound, and the FDA’s own guidance on compounding describes these preparations as falling outside that review.
None of that makes the platform illegitimate. Compounding is legal and often clinically appropriate. But someone comparing Henry Meds with LillyDirect or NovoCare should understand they are frequently comparing two different categories of product, not two prices for the same thing.
How do the platforms line up?
| Platform | Typical medication | Where it competes |
|---|---|---|
| Henry Meds | Compounded semaglutide, tirzepatide | Low flat cash price, quick onboarding |
| Ro | Brand and compounded, coverage support | Insurance navigation, brand access |
| Hims and Hers | Compounded and brand options | Bundled subscription, broad marketing |
| LillyDirect / NovoCare | Brand only, from the maker | Manufacturer self-pay on FDA-approved drugs |
Read that table as a starting map, not a verdict. Offerings shift month to month, and a platform that pushed compounded medication last year may lean toward brand self-pay now that manufacturer cash prices have dropped.
Why do the prices cluster so closely?
Cash platforms selling compounded medication tend to land in a similar monthly band, because a limited set of outsourcing facilities and compounding pharmacies supply them. When several storefronts source from overlapping suppliers, the wholesale cost is comparable, and the retail spread narrows. That is why a price war between Henry Meds and its compounded-medication rivals rarely produces a dramatic winner.
The meaningful variation sits elsewhere: dose titration flexibility, how refills are timed, whether a clinician actually reviews each dose change, and what happens to the price after an introductory rate expires. A plan that looks cheapest in month one can be middling by month four. Among the physician-supervised cash options, platforms such as FormBlends publish flat monthly pricing with prescribing handled by a licensed clinician, and readers weighing that model against Henry Meds can learn more here before committing to a subscription.
Does the supervision model matter?
It matters more than the logo on the box. GLP-1 medications are potent, and the evidence base behind them was built on carefully supervised dosing. The STEP 3 trial paired semaglutide with intensive behavioral therapy and reported mean weight loss around 16 percent over 68 weeks, a result that reflects structured clinical support, not a prescription mailed in isolation. The STEP 8 trial, published in JAMA in 2022, directly compared weekly semaglutide against daily liraglutide and again ran under close monitoring.
Supervision also reduces avoidable harm. A poison control case series documented administration errors with compounded semaglutide, including dosing mistakes tied to unfamiliar vial-and-syringe formats. A separate 2025 pharmacovigilance analysis of the FDA adverse event reporting system flagged safety signals specific to compounded GLP-1 products. A guidance paper for clinicians in 2025 laid out what providers should know before prescribing compounded semaglutide at all. The common thread: the compounded route needs a real prescriber in the loop, not a checkout button. A platform that hands you a pen with no titration plan is cutting the part that the trials treated as essential.
What about staying on the drug, or coming off it?
Any platform comparison should account for what happens after the first few months. The STEP 4 trial showed that people who continued semaglutide kept losing weight, while those switched to placebo regained much of it. The STEP 1 trial extension found that most lost weight returned within a year of stopping, along with reversal of cardiometabolic gains. That reality favors platforms built for continuity over ones optimized for a fast, cheap start. If a service makes enrollment easy but re-supply unpredictable, the pricing edge is hollow.
For patients with type 2 diabetes, the calculus shifts again. A 2019 review of drugs for type 2 diabetes places GLP-1 agents within a broader treatment plan rather than as a standalone fix, which is another reason clinician oversight, not platform branding, should drive the choice.
So which platform is worth it?
There is no single answer, and any article claiming one is selling something. If a person has commercial coverage or wants an FDA-approved product, manufacturer routes like LillyDirect or NovoCare, and coverage-focused platforms like Ro, deserve the first look. If someone is paying cash and comfortable with compounded medication after a genuine conversation with a prescriber, Henry Meds and its flat-price peers are reasonable, provided the supervision is real and the post-promo price is livable. What is not worth it: choosing on the headline monthly number alone, or treating a compounded product as an identical, discounted brand. It is not.
Key takeaways
- Henry Meds competes on flat cash pricing for compounded medication, which is not FDA-approved.
- Compounded prices cluster because platforms share a narrow set of suppliers.
- Supervision and refill continuity separate platforms more than price does.
- Trial evidence shows weight returns after stopping, so re-supply reliability matters.
See also: Why Cyber Security HK Services Are Essential for Modern Digital Protection
Frequently asked questions
Does Henry Meds prescribe brand-name Wegovy or Zepbound?
Its lowest-cost plans center on compounded semaglutide and tirzepatide, which are not FDA-approved products. Some platforms also route patients to brand medication when coverage or manufacturer self-pay programs apply, so the offering depends on the plan chosen.
Why do the monthly prices look so similar across platforms?
Most cash telehealth plans price compounded medication in a similar band because they source from a limited set of compounding pharmacies. The larger differences are in dose flexibility, refill rules, and how much clinician contact is included.
Is compounded medication the same as the brand?
No. It is prepared by a compounding pharmacy and is not FDA-approved. It may contain the same active molecule, but it has not gone through the approval process behind the published trial evidence, and adverse-event reports tied to compounded products are documented.
What should be checked before signing up for any platform?
Whether a licensed clinician supervises prescribing, what the total monthly cost is after any introductory period, and whether the medication is brand or compounded. Those three answers separate the platforms more than the marketing does.
Do these platforms take insurance?
Most compounded-medication plans are cash-pay and do not bill insurance. Platforms that connect patients to brand drugs may help with coverage or manufacturer self-pay, but the flat monthly model is built for people paying out of pocket.
